New combo drug trial hopes to shrink Hard-to-Treat cancers

NCT ID NCT07615660

Not yet recruiting Disease control Sponsor: Convalife (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CVL006 combined with 9MW2821
What this could lead to: If it works, this could point toward a new drug combination to shrink advanced solid tumors that have not responded to standard treatments.
What could go wrong: This is an early-phase trial with only 108 participants, so it is too soon to know if the combination is safe or effective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

More trials for these conditions

Other studies related to the condition(s) this trial covers.